| ²é¿´: 617 | »Ø¸´: 0 | ||
[ÇóÖú]
¡¶½á¹¹»¯Ñ§¡·ÔÓÖ¾²Î¿¼ÎÄÏ×ÐÞ¸ÄÇóÖú
|
|
¡¶½á¹¹»¯Ñ§¡·ÔÓÖ¾²Î¿¼ÎÄÏ×ÐÞ¸ÄÇóÖú£¬Ö÷±à˵¸ñʽ²»¶Ô£¬ÎÒÒѾУ¶Ô¹ýÁË£¬µ«Ã»·¢ÏÖÎÊÌ⣬¸ßÊÖ¿ÉÒÔ°ïÎÒ¿´ÏÂÂð£¿Ð»Ð»£¡ Fr¨ªas-Gonz¨¢lez, S. E.; Angeles-Anguiano, E.; Mendoza-Herrera, A.; Escutia-Calzada, D.; Ordaz-Pichardo, C. Cytotoxic, pro-apoptotic, pro-oxidant, and non-genotoxic activities of a novel copper(II) complex against human cervical cancer. Toxicology. 2013, 314, 155¨C165. Florea, A. M.; B¨¹sselberg, D. Cisplatin as an Anti-Tumor Drug: Cellular Mechanisms of Activity, Drug Resistance and Induced Side Effects. Cancers. 2011, 3, 1351¨C1371. Gielen, M.; Tiekink (Eds.), E. R. T. Metallotherapeutic Drugs and Metal-based Diagnostic Agents: The Use of Metals in Medicine. New York: Wiley, 2005, P 1¨C17. Devereux, M.; O¡¯Shea, D.; O¡¯Connor, M.; Grehan, H. Synthesis, catalase, superoxide dismutase and antitumour activities of copper(II) carboxylate complexes incorporating benzimidazole, 1,10-phenanthroline and bipyridine ligands: X-ray crystal structures of [Cu(BZA)2(bipy)(H2O)], [Cu(SalH)2(BZDH)2] and [Cu(CH3COO)2(5,6-DMBZDH)2] (SalH2 = salicylic acid; BZAH = benzoic acid; BZDH = benzimidazole and 5,6-DMBZDH = 5,6-dimethylbenzimidazole). Polyhedron. 2007, 26, 4073¨C4084. McCann, M.; Coyle, B.; McKay, S.; McCormack, P.; Kavanagh, K.; Devereux, M.; McKee, V.; Kinsela, P.; Connor, R. O.; Clynes, M. Synthesis and X-ray crystal structure of [Ag(phendio)2]ClO4 (phendio = 1,10-phenanthroline-5,6-dione) and its effects on fungal and mammalian cells. Biometals. 2004, 17, 635¨C654. Huang, R. L.; Wallqvist, A.; Covell, D. G. Anticancer metal compounds in NCI's tumor-screening database: putative mode of action. Biochemical Pharmacology. 2005, 69, 1009¨C1039. Wu, H. L.; Yuan, J. K.; Bai, Y.; Wang, H.; Pan, G. L.; Kong, J. A seven-coordinated manganese(II) complex with V-shaped ligand bis(N-benzylbenzimidazol-2-ylmethyl)benzylamine: Synthesis, structure, DNA-binding properties and antioxidant activities. J. Photoch. Photobio. B. 2012, 116, 13¨C21. Wu, H. L.; Yuan, J. K.; Pan, G. L. The V-shaped ligand bis(N-allylbenzimidazol-2-ylmethyl)benzylamine and its Ag(I) complex: Synthesis, crystal structure, DNA-binding properties and antioxidation. J. Photoch. Photobio. B. 2013, 122, 37¨C 44. Kaniskan, N.; Ogretir, C. Investigation of acid¨Cbase behaviour of some 2-pyridylbenzimidazoles using semi-empirical methods. J. Mol. Struct. 2002, 584, 45¨C52. Sączewski, F.; Dziemidowicz-Borys, E.; Bednarski, P. J. Synthesis, crystal structure and biological activities of copper(II) Complexes with chelating bidentate 2-substituted benzimidazole ligands. Journal of Inorganic Biochemistry. 2006, 100, 1389 ¨C1398. Rowan, R.; Moran, C.; McCann, M.; Kavanagh, K. Use of Galleria mellonella larvae to evaluate the in vivo anti-fungal activity of [Ag2(mal)(phen)3]. BioMetals. 2009, 22, 461¨C 467. McCann, M.; Geraghty, M.; Devereux, M.; O¡¯Shea, D.; Mason., J.; O¡¯Sullivan, L. Insights Into the Mode of Action of the Anti-Candida Activity of 1,10-Phenanthroline and its Metal Chelates. Metal-Based Drugs. 2000, 7, 185¨C193. Deegan, C.; Coyle, B.; McCann, M.; Devereux, M.; Egan, D. In vitro anti-tumour effect of 1,10-phenanthroline-5,6-dione (phendione), [Cu(phendione)3](ClO4)2¡¤4H2O and [Ag(phendione)2]ClO4 using human epithelial cell lines. Chem. Biol. Interact. 2006, 164, 115¨C125. Cerchiaro, G.; Aquilano, K.; Filomeni, G. Isatin-Schiff base copper(II) complexes and their influence on cellular viability. Journal of Inorganic Biochemistry. 2005, 99, 1433-1440. Puszy¨½ska-Tuszkanow, M.; Grabowski, T.; Daszkiewicz, M. Silver(I) complexes with hydantoins and allantoin ¡î: Synthesis, crystal and molecular structure, cytotoxicity and pharmacokinetics. Journal of Inorganic Biochemistry. 2011, 105, 17¨C22. |
» ²ÂÄãϲ»¶
̨ÖÝѧԺÓÐÐò¶à¿×²ÄÁÏÍŶÓ×îºó³å´Ì£¬Í¬Ñ§ÃDZð´í¹ýŶ£¬ÇëËÙÁªÏµ£¡
ÒѾÓÐ0È˻ظ´
½Î÷¿Æ¼¼Ê¦·¶´óѧÎïÀí»¯Ñ§¿ÎÌâ×é½ÓÊÕµ÷¼ÁÉú£¬Ãû¶î»¹ÓУ¬ËÙÀ´
ÒѾÓÐ0È˻ظ´
ÎÞ»ú»¯Ñ§ÂÛÎÄÈóÉ«/·ÒëÔõôÊÕ·Ñ?
ÒѾÓÐ126È˻ظ´
Çó̼ËáÄÆºÍ̼ËáÇâÄÆµÄ¾§°û½á¹¹Í¼»ò¾§Ìå½á¹¹Í¼
ÒѾÓÐ0È˻ظ´
Çó̼ËáÄÆºÍ̼ËáÇâÄÆµÄ¾§°û½á¹¹Í¼»ò¾§Ìå½á¹¹Í¼
ÒѾÓÐ0È˻ظ´
½Î÷¿Æ¼¼Ê¦·¶´óѧÎïÀí»¯Ñ§¿ÎÌâ×é½ÓÊÕµ÷¼ÁÉú£¬12µã¿ªÆô£¬ËÙÀ´
ÒѾÓÐ0È˻ظ´
¡¾2026 ¿¼Ñе÷¼Á¡¿¹þ¶û±õ¹¤³Ì´óѧ ÕÐÊÕѧ˶µ÷¼ÁÉú£¨Ó¢ÓïÒ»¡¢Êýѧһ£©
ÒѾÓÐ0È˻ظ´
ËÄ´¨Çữ¹¤´óѧ»¯Ñ§Óë»·¾³¹¤³ÌѧԺ ¸¶êŽÌÊÚ¿ÎÌâ×éÕÐÊÕµ÷¼Á˶ʿÑо¿Éú
ÒѾÓÐ11È˻ظ´
Ñγǹ¤Ñ§Ôº²ÄÁÏ¿ÆÑ§Ó빤³ÌѧԺ½»Í¨ÔËÊäרҵ˶ʿÑо¿Éúµ÷¼ÁÕÐÉú
ÒѾÓÐ0È˻ظ´
ÕÒµ½Ò»Ð©Ïà¹ØµÄ¾«»ªÌû×Ó£¬Ï£ÍûÓÐÓÃŶ~
ÇëÎÊÕâÖֲο¼ÎÄÏ׸ñʽÔõô¿ìËÙÐ޸ģ¿
ÒѾÓÐ4È˻ظ´
ÇóÖúÐÞ¸ÄÍâÎÄÎÄÏ׵IJο¼ÎÄÏ׸ñʽ
ÒѾÓÐ7È˻ظ´
ÇóÖúһƪ½á¹¹»¯Ñ§ÆÚ¿¯ÉϵÄÎÄÏ×
ÒѾÓÐ3È˻ظ´
ÇóÖúNoteExpress2²Î¿¼ÎÄÏ×µÄÎÊÌ⣬лл¡£
ÒѾÓÐ6È˻ظ´
ÇóÖú:´óÐÞ¶þÉóºó£¬±à¼ÒªÇóÐ޸IJο¼ÎÄÏ×£¬ ÕâÖÖÇé¿öÏ»¹¿ÉÒÔÐÞ¸ÄÎÄÕÂÆäËûÄÚÈÝÂð£¿
ÒѾÓÐ6È˻ظ´
ÆÚ¿¯ÒªÇó²Î¿¼ÎÄÏ× ÆÚ¿¯Ð´¼òд£¿È¥ÄÄÀï²éÆÚ¿¯Ó¢ÎĵļòÐ´ÄØ
ÒѾÓÐ5È˻ظ´
¹ØÓÚenergy policy ÆÚ¿¯ ²Î¿¼ÎÄÏ׸ñʽ
ÒѾÓÐ17È˻ظ´
ԤͶRSCÆÚ¿¯£¬¹ØÓÚÆä²Î¿¼ÎÄÏ׸ñʽ
ÒѾÓÐ7È˻ظ´
Éó¸åÈËͬÒâ½ÓÊÜ£¬ÈüӲο¼ÎÄÏ×
ÒѾÓÐ15È˻ظ´
¸ßµÈѧУ»¯Ñ§Ñ§±¨µÄ²Î¿¼ÎÄÏ׸ñʽ
ÒѾÓÐ3È˻ظ´
proofÇóÖú£º²Î¿¼ÎÄÏ××÷Õ߸ñʽÎÊÌ⣿
ÒѾÓÐ8È˻ظ´
ÇóÖú²Î¿¼ÎÄÏ×д·¨£¬ÊÇÆÚ¿¯»¹ÊÇÊéÄØ£¿
ÒѾÓÐ4È˻ظ´
ÍâÎÄÔÓÖ¾±à¼ÒªÇó°Ñ²Î¿¼ÎÄÏ×ÖеÄһƪ´óÂÛÎĸÄΪ¿ÉÒýÓõÄСÂÛÎÄ£¬ÕÒ²»µ½ºÏÊʵģ¬Ôõô°ì
ÒѾÓÐ10È˻ظ´
ÂÛÎIJο¼ÎÄÏ×ÐÞ¸ÄÇóÖú
ÒѾÓÐ16È˻ظ´
Biosensors and Bioelectronics ²Î¿¼ÎÄÏ×ÓÃEedNoteÔõô²åÈë
ÒѾÓÐ4È˻ظ´
ÎÄÕÂÔÚÐ޸ģ¬Éó¸ãÈË˵²Î¿¼ÎÄÏ×ÒýÓõò»ºÃ£¬ÎÒÓ¦¸ÃÈçºÎ¸Ä²¢ÈçºÎ»Ø¸´ËûÄØ
ÒѾÓÐ15È˻ظ´
ieee ÆÚ¿¯²Î¿¼ÎÄÏ׸ñʽ
ÒѾÓÐ8È˻ظ´
ÇóÖúscience chinaÆÚ¿¯ÒýÓòο¼ÎÄÏ׵ĸñʽÎÊÌâ
ÒѾÓÐ10È˻ظ´
²Î¿¼ÎÄÏ×±àдÇóÖú
ÒѾÓÐ10È˻ظ´
ÇóÖú£ºProof·¢À´·¢ÏÖһƪ²Î¿¼ÎÄÏ×·¢±íÄê·Ýд´í£¬ÎÊÌâ´óÂð£¿
ÒѾÓÐ8È˻ظ´
Endnonte ±à¼²Î¿¼ÎÄÏ×ÇóÖú ¼±¼±
ÒѾÓÐ6È˻ظ´
Çó×îеĽṹ»¯Ñ§Í¶¸åÐëÖª
ÒѾÓÐ7È˻ظ´
¹ØÓڲο¼ÎÄÏ×µÄÊýÁ¿
ÒѾÓÐ4È˻ظ´
¹úÄÚÔÓÖ¾¡¶·ÖÎö»¯Ñ§¡·Í¶¸åÇóÖú
ÒѾÓÐ4È˻ظ´
ÍËÐÞÖØÉ󣬱à¼ÒªÇó¼Ó¸ÃÆÚ¿¯µÄ²Î¿¼ÎÄÏ×£¬²»ºÃ¼Ó°¡
ÒѾÓÐ27È˻ظ´
¹ØÓڲο¼ÎÄÏ×ÖеÄÖÐÎÄ
ÒѾÓÐ22È˻ظ´
¿ÆÑдÓСľ³æ¿ªÊ¼£¬ÈËÈËΪÎÒ£¬ÎÒΪÈËÈË













»Ø¸´´ËÂ¥
µã»÷ÕâÀïËÑË÷¸ü¶àÏà¹Ø×ÊÔ´